登录 | 注册    关注公众号  
微信公众号
搜索
 >  Antibody>SN38 >SN8-M685

Monoclonal Anti-SN38 Antibody, Mouse IgG1 (MALS verified)

抗体来源(Source)

Monoclonal Anti-SN38 Antibody, Mouse IgG1 is a Mouse monoclonal antibody recombinantly expressed from HEK293 cells.

种属(Species)

Mouse

亚型(Isotype)

Mouse IgG1 | Mouse Kappa

偶联(Conjugate)

Unconjugated

抗体类型(Antibody Type)

Recombinant Monoclonal

种属反应性(Reactivity)

Chemical

免疫原(Immunogen)

SN38-OVA.

特异性(Specificity)

Specifically recognizes the target-SN38.

应用(Application)

ApplicationRecommended Usage
ELISA0.1-8 ng/mL 

纯度(Purity)

>90% as determined by SDS-PAGE.

>95% as determined by SEC-MALS.

纯化(Purification)

Protein A purified / Protein G purified

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

交叉验证(Cross Verification)

This product No cross-reactivity in ELISA with
Trastuzumab Deruxtecan. Disitamab Vedotin (RC48). Trastuzumab-DM1.

 

电泳(SDS-PAGE)

SN38 SDS-PAGE

Monoclonal Anti-SN38 Antibody, Mouse IgG1 on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS

SN38 SEC-MALS

The purity of Monoclonal Anti-SN38 Antibody, Mouse IgG1 (Cat. No. SN8-M685) is more than 95% and the molecular weight of this protein is around 130-160 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

SN38 ELISA

Immobilized Sacituzumab govitecam at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-SN38 Antibody, Mouse IgG1 (Cat. No. SN8-M685) with a linear range of 0.12-0.98 ng/mL (QC tested).

Protocol

SN38 ELISA

Immobilized Monoclonal Anti-SN38 Antibody, Mouse IgG1 (Cat. No. SN8-M685) at 1 μg/mL, add Sacituzumab Govitecam in the 50% Mouse serum and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).

Protocol

 
评论(0)
 
ACRO质量管理体系
 
 

背景(Background)

The 7-ethyl-10-hydroxycamptothecin (SN-38) is a topoisomerase I inhibitor (chemotherapeutic agent) used in cancer therapy. In a comparative study of SN-38 with a potent chemotherapeutic prodrug, irinotecan (CPT-11), SN-38 was found to be 1000-fold more cytotoxic against colorectal cancer cells as compared to irinotecan.

 

前沿进展

HER2-targeted star polymer conjugates for improved tumor distribution and efficacy
Sonzini, England, Kapustin et al
J Control Release (2025)
Abstract: Actively targeted nanoparticle systems have the potential to improve delivery to tumors over untargeted systems however the design rules to achieve this have not been fully elucidated. A HER2-targeted polymer drug delivery system composed of a 32-arm star polymer (SD) conjugated with the TOP1 inhibitor molecule SN-38, with a trastuzumab antigen binding fragment (HER2-Fab), has been used to target cancer cells overexpressing this receptor. The HER2-Fab was attached to the SD at two different densities (average of 1 or 3 Fabs per star polymer) and compared to the native star polymer without Fab. In vitro experimentation showed that both the targeted star polymers (HER2-SDs) had better binding and uptake in HER2-positive cell lines (SK-BR3 and HEK293) compared to the non-targeted SD. In vivo biodistribution studies showed enhanced accumulation of HER2-targeted SDs in tumors, but not normal tissues, particularly at the later (96 h post-dose) timepoint. The HER2-SDs demonstrated increased localization with tumor cells rather than in stromal regions, greater penetration into the tumor core and a more homogenous distribution in the tumor section than the untargeted SD. The targeted star polymer conjugated to SN-38 was tested for anti-tumor activity in a HER2-positive gastric cancer xenograft in mice and showed significantly greater efficacy compared to untargeted SDs.Copyright © 2025. Published by Elsevier B.V.
Rational Design of Bioinspired Lipoprotein System to Improve Penetration in Colorectal Peritoneal Metastases
Chi, Lu, Wu et al
Nano Lett (2025)
Abstract: Chemotherapy of lethal colorectal peritoneal metastases (PM) is notoriously challenged by poor drug delivery efficiency in PM tumors. Inspired by the histopathological examinations of PM tumors from colon cancer patients, a C[RGDfK] peptide-modified bioinspired lipoprotein (R-BLP) system was optimized from 8 formulations with profound penetrating ability in PM tumors of colorectal cancers. Then, a chemotherapeutic 7-ethyl-10-hydroxy-camptothecin (SN38)-loaded R-BLP (termed SR-BLP) was designed to promote their penetration in PM tumors and improve the chemotherapeutic efficacy. In CT26-induced PM models, SR-BLP exhibited better penetration profiles in PM tumors over a counterpart liposomal formulation. SR-BLP treatment produced an 80.03% suppression of PM incidence with obvious DNA damage and topoisomerase I (TOP I) downregulation and caused a 1.78-fold prolongation of survival time. Therefore, the histopathological features-inspired R-BLP provides an encouraging tumor-penetrating delivery platform for the effective chemotherapy of colorectal PM.
Fabrication of Bioconjugates Clacked Chitosan-Coated SN-38 Liposomal Nanoparticles: Improved Precise Chemotherapy Efficacy in Lung Cancer Cells and Its Apoptosis
Zhang, Sun, Liu
Biotechnol Appl Biochem (2025)
Abstract: Employing an active targeting method with monoclonal antibodies for chemotherapeutics-loaded nanocarriers represents a promising option to enhance the specific drug delivery and alleviate the detrimental effects of chemotherapeutic agents. Targeted delivery to the human epidermal growth factor receptor-2 (HER2), which is overexpressed in HER2+ lung cancerous cells, can be accomplished by conjugating nanoparticles with a monoclonal antibody (anti-HER2). We developed trastuzumab (TZ)-conjugated chitosan iodoacetamide (CsIA)-coated liposomal nanoparticles carrying SN-38 (TZ-SN-CsIA LNPs) as a lung-targeted delivery. CsIA was used to develop trastuzumab-clacked nanoparticles (TZ LNPs). The structure, physicochemical characteristics, SN-38 encapsulation, SN-38 release, and anticancer properties of the LNPs were established. The TZ LNPs were spherical, measuring around 77 nm in diameter, and exhibited a positive zeta potential; upon drug incorporation, the diameter of the TZ LNPs enlarged. A sustained, 24-h SN-38 release from the nanocarriers was accomplished. TZ LNPs demonstrated substantial cellular accumulation and markedly enhanced anticancer efficacy against HER2+ Calu-3 lung adenocarcinoma cancer cells compared to the drug solution and unconjugated LNPs. Consequently, TZ-SN-CsIA LNPs may be a potential nanocarrier for HER2+ lung cancer.© 2025 International Union of Biochemistry and Molecular Biology, Inc.
Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC) payloads in bladder cancer
P Shanmugam, Zhou, Stelter et al
Bladder Cancer (2025) 11 (1), 23523735251317865
Abstract: Enfortumab vedotin (EV) and Sacituzumab govitecan (SG) are antibody-drug conjugates (ADCs) with demonstrated activity in advanced bladder cancer. A subset of bladder tumors harbors a DNA repair deficiency in either the homologous recombination (HR) or nucleotide excision repair (NER) pathway that has the potential to impact sensitivity to specific classes of therapeutics.Define the impact of HR or NER deficiency on sensitivity to ADC payloads alone or in combination with DNA repair targeted agents in bladder cancer.Isogenic cell pairs with versus without HR or NER deficiency were profiled using DNA repair and drug sensitivity assays. Sensitivity to the ADC payloads monomethyl auristatin E (MMAE) and SN-38 alone or in combination with small molecule inhibitors of poly(ADP-ribose) polymerase (PARP), ATR, or USP1 were measured using cell viability assays.BRCA2 loss was sufficient to confer an HR deficient phenotype and increase sensitivity to cisplatin and PARP inhibition in bladder cancer cell lines. HR deficiency, but not NER deficiency, increased sensitivity to MMAE and SN-38 in bladder cancer cells. The combination of SN-38 and PARP inhibition displayed synergistic cell killing independent of HR or NER status.HR and NER deficiency have distinct impacts on sensitivity to cisplatin and ADC payloads in bladder cancer preclinical models.© The Author(s) 2025.
Showing 1-4 of 2301 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
前沿进展
点击查看详细
相关产品
View All SN38

消息提示

请输入您的联系方式,再点击提交!

确定